top of page
.jpg){kind=logo}
Recent News
Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025
Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for shock and trauma, announced its participation in BIO...
Selective nitric oxide redistribution by phospholipid nanoparticles: A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock
Free Radical Biology and Medicine Volume 227 , 1 February 2025, Pages 276-281 https://www.sciencedirect.com/science/article/abs/pii/S0891...
Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals
KANSAS CITY, Mo., Sept. 24, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...
1 min read
Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025
Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for shock and trauma, announced its participation in BIO...
1 min read
Selective nitric oxide redistribution by phospholipid nanoparticles: A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock
Free Radical Biology and Medicine Volume 227 , 1 February 2025, Pages 276-281 https://www.sciencedirect.com/science/article/abs/pii/S0891...
1 min read
Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals
KANSAS CITY, Mo., Sept. 24, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...
1 min read
1 min read
Vivacelle Bio Enrolls First Patient in Phase 3 Trial of Hypovolemia Due to Septic Shock for Phospholipid Nanoparticle-Based VBI-S
KANSAS CITY, Mo., Sept. 3, 2024 /PRNewswire/ -- Vivacelle Bio , a late-stage biopharma company developing life-saving treatments for...
1 min read
Surge in Septic Shock Care: Vivacelle’s Innovative Approach
https://www.clinicaltrialvanguard.com/executiveinterviews/surge-in-septic-shock-care-vivacelles-innovative-approach/
1 min read
Vivacelle Bio Initiates Phase 3 Trial for Lead Asset VBI-S to Treat Patients with Hypovolemia Due to Septic Shock
https://www.prnewswire.com/news-releases/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-du...
3 min read
Vivacelle Bio's President and Chief Innovation Officer to Present Data Highlighting the Company's Late-Stage Clinical Programs at the BIO International Convention 2024
Vivacelle is advancing a robust pipeline of therapies for shock and trauma-induced conditions Vivacelle's pipeline is led by VBI-S, a...
1 min read
Sepsis is to blame for the 40-year-old mother's unexpected death. It sheds light on broader maternal healthcare issues for Black women.
https://21ninety.com/krystal-anderson-sepsis-death-stillbirth
4 min read
Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients
KANSAS CITY, Mo., Feb. 29, 2024 /PRNewswire/ -- Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed...
1 min read
Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round
https://www.prnewswire.com/news-releases/vivacelle-bio-integrates-sub-saharan-africa-strategy-into-series-b-financing-round-302067989.html
1 min read
Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats
Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats. https://www.fiercehealthcare.com/providers/feds-hope-cut...
1 min read
The Lancet Journal - Efficacy and safety of phospholipid nanoparticles (VBI-S) in reversing intractable hypotension in patients with septic shock: a multicentre, open-label, repeated measures, phase 2
Published: January 29, 2024 https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00009-9/fulltext
3 min read
Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients
KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of...
3 min read
Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem
By GetNews Published September 19, 2022 DelveInsight’s “Septic Shock Market Insights, Epidemiology, and Market Forecast-2032″ report...
0 min read
3 min read
Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangibotide (LR12): Inotrem, Allocetra: Enlivex Therapeutics
Published May 9, 2022 New Jersey, United States-Sepsis and Shock Treatment Market – Global Industry Analysis, Size, Share, Growth,...
bottom of page